Related Experiment Video
Updated: Jun 30, 2025
04:48
Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
Published on: January 7, 2015
7.4K
Colchicine's Role in Cardiovascular Disease Management
1Department of Pharmacy (L.F.B.), Brigham and Women's Hospital, Boston, MA.
Arteriosclerosis, Thrombosis, and Vascular Biology
|March 21, 2024
Summary
Low-dose colchicine effectively manages cardiovascular inflammation and prevents adverse events, marking a significant advance in treating atherosclerotic cardiovascular disease. Careful monitoring is essential for safe and effective use.
Area of Science:
- Cardiology
- Pharmacology
- Inflammation Research
Background:
- Colchicine, an ancient alkaloid, has evolved from gout treatment to a cardiovascular anti-inflammatory therapy.
- Recent research highlights low-dose colchicine's efficacy in acute gout, pericarditis, and secondary cardiovascular event prevention.
Purpose of the Study:
- To review colchicine's current role in managing atherosclerotic cardiovascular disease.
- To discuss the implications of colchicine as the first FDA-approved targeted anti-inflammatory cardiovascular therapy.
Main Methods:
- Literature review of colchicine's historical and contemporary applications in cardiovascular medicine.
- Analysis of clinical trial data supporting colchicine's efficacy and safety in cardiovascular conditions.
Main Results:
- Low-dose colchicine demonstrates effectiveness in treating gout flares, reducing recurrent pericarditis, and preventing major adverse cardiovascular events.
- Colchicine is recognized as a unique targeted anti-inflammatory therapy for atherosclerotic cardiovascular disease.
Conclusions:
- Colchicine offers a novel therapeutic option for atherosclerotic cardiovascular disease management.
- Safe use necessitates monitoring for drug interactions, organ function, and gastrointestinal side effects.
- Future research should explore mechanisms, primary prevention, other cardiometabolic conditions, and personalized therapy.
Related Concept Videos
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
2.8K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.8K
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
500
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
500
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
522
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
522
01:26Heart Failure Drugs: Inotropic Agents
578
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
578
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
832
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
832
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K